Continuing to strengthen FDA's science approach to emerging technologies
Abstract Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investme...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine 2013-07, Vol.9 (5), p.594-599 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 599 |
|---|---|
| container_issue | 5 |
| container_start_page | 594 |
| container_title | Nanomedicine |
| container_volume | 9 |
| creator | Anatol, Rachael, PhD Bauer, Steven, PhD Epstein, Suzanne, PhD Filice, Ross, MD Lauritsen, Kristina, PhD Lee, Mark H., PhD Mansfield, Elizabeth, PhD McMurry-Heath, Michelle, PhD Milone, Joseph, PhD Peña, Carlos, PhD Pollack, Steven, PhD Zineh, Issam, PharmD, MPH, FCCP |
| description | Abstract Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health. |
| doi_str_mv | 10.1016/j.nano.2013.04.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500772897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1549963413001779</els_id><sourcerecordid>1371271766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-f1a3a57397b89f5e75f64b77f3a13418d3264181d23e392290d876aa046f3033</originalsourceid><addsrcrecordid>eNqFkU1vEzEQhi0Eoh_wBzigvcEly9jjtWMJIVWBUqRKHOjdcryzicPGDvZupf57dknaAwc4zRye99XoGcbecKg5cPVhV0cXUy2AYw2yBmiesXPeSLMwSornTzvKM3ZRyg4ANYB5yc4EKiOU0efsZpXiEOIY4qYaUlWGTHEzbClW15-v3pWq-EDRU-UOh5yc384Q7Slv_gTIb2Pq0yZQecVedK4v9Po0L9nd9Ze71c3i9vvXb6ur24WXUg6Ljjt0jUaj10vTNaSbTsm11h06jpIvWxRqGrwVSGiEMNAutXIOpOoQEC_Z-2PtdM6vkcpg96F46nsXKY3F8gZAa7E0-v8oai4010pNqDiiPqdSMnX2kMPe5QfLwc6u7c7Oru3s2oK0k-sp9PbUP6731D5FHuVOwMcjQJOP-0DZnmy2IZMfbJvCv_s__RX3fYjBu_4nPVDZpTHHybTltggL9sf87fnZHAG41gZ_AzJQoss</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1371271766</pqid></control><display><type>article</type><title>Continuing to strengthen FDA's science approach to emerging technologies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Anatol, Rachael, PhD ; Bauer, Steven, PhD ; Epstein, Suzanne, PhD ; Filice, Ross, MD ; Lauritsen, Kristina, PhD ; Lee, Mark H., PhD ; Mansfield, Elizabeth, PhD ; McMurry-Heath, Michelle, PhD ; Milone, Joseph, PhD ; Peña, Carlos, PhD ; Pollack, Steven, PhD ; Zineh, Issam, PharmD, MPH, FCCP</creator><creatorcontrib>Anatol, Rachael, PhD ; Bauer, Steven, PhD ; Epstein, Suzanne, PhD ; Filice, Ross, MD ; Lauritsen, Kristina, PhD ; Lee, Mark H., PhD ; Mansfield, Elizabeth, PhD ; McMurry-Heath, Michelle, PhD ; Milone, Joseph, PhD ; Peña, Carlos, PhD ; Pollack, Steven, PhD ; Zineh, Issam, PharmD, MPH, FCCP</creatorcontrib><description>Abstract Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health.</description><identifier>ISSN: 1549-9634</identifier><identifier>EISSN: 1549-9642</identifier><identifier>DOI: 10.1016/j.nano.2013.04.005</identifier><identifier>PMID: 23692697</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Emerging technologies ; FDA ; Humans ; Internal Medicine ; Investments - economics ; Nanotechnology - economics ; Public Health ; Research - economics ; Science ; United States ; United States Food and Drug Administration - economics</subject><ispartof>Nanomedicine, 2013-07, Vol.9 (5), p.594-599</ispartof><rights>2013</rights><rights>Copyright © 2013. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-f1a3a57397b89f5e75f64b77f3a13418d3264181d23e392290d876aa046f3033</citedby><cites>FETCH-LOGICAL-c444t-f1a3a57397b89f5e75f64b77f3a13418d3264181d23e392290d876aa046f3033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1549963413001779$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23692697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anatol, Rachael, PhD</creatorcontrib><creatorcontrib>Bauer, Steven, PhD</creatorcontrib><creatorcontrib>Epstein, Suzanne, PhD</creatorcontrib><creatorcontrib>Filice, Ross, MD</creatorcontrib><creatorcontrib>Lauritsen, Kristina, PhD</creatorcontrib><creatorcontrib>Lee, Mark H., PhD</creatorcontrib><creatorcontrib>Mansfield, Elizabeth, PhD</creatorcontrib><creatorcontrib>McMurry-Heath, Michelle, PhD</creatorcontrib><creatorcontrib>Milone, Joseph, PhD</creatorcontrib><creatorcontrib>Peña, Carlos, PhD</creatorcontrib><creatorcontrib>Pollack, Steven, PhD</creatorcontrib><creatorcontrib>Zineh, Issam, PharmD, MPH, FCCP</creatorcontrib><title>Continuing to strengthen FDA's science approach to emerging technologies</title><title>Nanomedicine</title><addtitle>Nanomedicine</addtitle><description>Abstract Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health.</description><subject>Emerging technologies</subject><subject>FDA</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Investments - economics</subject><subject>Nanotechnology - economics</subject><subject>Public Health</subject><subject>Research - economics</subject><subject>Science</subject><subject>United States</subject><subject>United States Food and Drug Administration - economics</subject><issn>1549-9634</issn><issn>1549-9642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1vEzEQhi0Eoh_wBzigvcEly9jjtWMJIVWBUqRKHOjdcryzicPGDvZupf57dknaAwc4zRye99XoGcbecKg5cPVhV0cXUy2AYw2yBmiesXPeSLMwSornTzvKM3ZRyg4ANYB5yc4EKiOU0efsZpXiEOIY4qYaUlWGTHEzbClW15-v3pWq-EDRU-UOh5yc384Q7Slv_gTIb2Pq0yZQecVedK4v9Po0L9nd9Ze71c3i9vvXb6ur24WXUg6Ljjt0jUaj10vTNaSbTsm11h06jpIvWxRqGrwVSGiEMNAutXIOpOoQEC_Z-2PtdM6vkcpg96F46nsXKY3F8gZAa7E0-v8oai4010pNqDiiPqdSMnX2kMPe5QfLwc6u7c7Oru3s2oK0k-sp9PbUP6731D5FHuVOwMcjQJOP-0DZnmy2IZMfbJvCv_s__RX3fYjBu_4nPVDZpTHHybTltggL9sf87fnZHAG41gZ_AzJQoss</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Anatol, Rachael, PhD</creator><creator>Bauer, Steven, PhD</creator><creator>Epstein, Suzanne, PhD</creator><creator>Filice, Ross, MD</creator><creator>Lauritsen, Kristina, PhD</creator><creator>Lee, Mark H., PhD</creator><creator>Mansfield, Elizabeth, PhD</creator><creator>McMurry-Heath, Michelle, PhD</creator><creator>Milone, Joseph, PhD</creator><creator>Peña, Carlos, PhD</creator><creator>Pollack, Steven, PhD</creator><creator>Zineh, Issam, PharmD, MPH, FCCP</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20130701</creationdate><title>Continuing to strengthen FDA's science approach to emerging technologies</title><author>Anatol, Rachael, PhD ; Bauer, Steven, PhD ; Epstein, Suzanne, PhD ; Filice, Ross, MD ; Lauritsen, Kristina, PhD ; Lee, Mark H., PhD ; Mansfield, Elizabeth, PhD ; McMurry-Heath, Michelle, PhD ; Milone, Joseph, PhD ; Peña, Carlos, PhD ; Pollack, Steven, PhD ; Zineh, Issam, PharmD, MPH, FCCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-f1a3a57397b89f5e75f64b77f3a13418d3264181d23e392290d876aa046f3033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Emerging technologies</topic><topic>FDA</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Investments - economics</topic><topic>Nanotechnology - economics</topic><topic>Public Health</topic><topic>Research - economics</topic><topic>Science</topic><topic>United States</topic><topic>United States Food and Drug Administration - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anatol, Rachael, PhD</creatorcontrib><creatorcontrib>Bauer, Steven, PhD</creatorcontrib><creatorcontrib>Epstein, Suzanne, PhD</creatorcontrib><creatorcontrib>Filice, Ross, MD</creatorcontrib><creatorcontrib>Lauritsen, Kristina, PhD</creatorcontrib><creatorcontrib>Lee, Mark H., PhD</creatorcontrib><creatorcontrib>Mansfield, Elizabeth, PhD</creatorcontrib><creatorcontrib>McMurry-Heath, Michelle, PhD</creatorcontrib><creatorcontrib>Milone, Joseph, PhD</creatorcontrib><creatorcontrib>Peña, Carlos, PhD</creatorcontrib><creatorcontrib>Pollack, Steven, PhD</creatorcontrib><creatorcontrib>Zineh, Issam, PharmD, MPH, FCCP</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anatol, Rachael, PhD</au><au>Bauer, Steven, PhD</au><au>Epstein, Suzanne, PhD</au><au>Filice, Ross, MD</au><au>Lauritsen, Kristina, PhD</au><au>Lee, Mark H., PhD</au><au>Mansfield, Elizabeth, PhD</au><au>McMurry-Heath, Michelle, PhD</au><au>Milone, Joseph, PhD</au><au>Peña, Carlos, PhD</au><au>Pollack, Steven, PhD</au><au>Zineh, Issam, PharmD, MPH, FCCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuing to strengthen FDA's science approach to emerging technologies</atitle><jtitle>Nanomedicine</jtitle><addtitle>Nanomedicine</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>9</volume><issue>5</issue><spage>594</spage><epage>599</epage><pages>594-599</pages><issn>1549-9634</issn><eissn>1549-9642</eissn><abstract>Abstract Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23692697</pmid><doi>10.1016/j.nano.2013.04.005</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-9634 |
| ispartof | Nanomedicine, 2013-07, Vol.9 (5), p.594-599 |
| issn | 1549-9634 1549-9642 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1500772897 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Emerging technologies FDA Humans Internal Medicine Investments - economics Nanotechnology - economics Public Health Research - economics Science United States United States Food and Drug Administration - economics |
| title | Continuing to strengthen FDA's science approach to emerging technologies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A22%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuing%20to%20strengthen%20FDA's%20science%20approach%20to%20emerging%20technologies&rft.jtitle=Nanomedicine&rft.au=Anatol,%20Rachael,%20PhD&rft.date=2013-07-01&rft.volume=9&rft.issue=5&rft.spage=594&rft.epage=599&rft.pages=594-599&rft.issn=1549-9634&rft.eissn=1549-9642&rft_id=info:doi/10.1016/j.nano.2013.04.005&rft_dat=%3Cproquest_cross%3E1371271766%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1371271766&rft_id=info:pmid/23692697&rft_els_id=1_s2_0_S1549963413001779&rfr_iscdi=true |